233 related articles for article (PubMed ID: 11857304)
1. p53 and Ki-67 as markers of radioresistance in head and neck carcinoma.
Couture C; Raybaud-Diogène H; Têtu B; Bairati I; Murry D; Allard J; Fortin A
Cancer; 2002 Feb; 94(3):713-22. PubMed ID: 11857304
[TBL] [Abstract][Full Text] [Related]
2. Markers of radioresistance in squamous cell carcinomas of the head and neck: a clinicopathologic and immunohistochemical study.
Raybaud-Diogène H; Fortin A; Morency R; Roy J; Monteil RA; Têtu B
J Clin Oncol; 1997 Mar; 15(3):1030-8. PubMed ID: 9060543
[TBL] [Abstract][Full Text] [Related]
3. Nuclear DNA content, an adjunct to p53 and Ki-67 as a marker of resistance to radiation therapy in oral cavity and pharyngeal squamous cell carcinoma.
Raybaud H; Fortin A; Bairati I; Morency R; Monteil RA; Têtu B
Int J Oral Maxillofac Surg; 2000 Feb; 29(1):36-41. PubMed ID: 10691142
[TBL] [Abstract][Full Text] [Related]
4. P53 and Ki-67 as outcome predictors for advanced squamous cell cancers of the head and neck treated with chemoradiotherapy.
Lavertu P; Adelstein DJ; Myles J; Secic M
Laryngoscope; 2001 Nov; 111(11 Pt 1):1878-92. PubMed ID: 11801963
[TBL] [Abstract][Full Text] [Related]
5. Heat shock protein and p53 expression in head and neck squamous cell carcinoma.
Gandour-Edwards R; Trock BJ; Gumerlock P; Donald PJ
Otolaryngol Head Neck Surg; 1998 May; 118(5):610-5. PubMed ID: 9591858
[TBL] [Abstract][Full Text] [Related]
6. Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapy.
Buffa FM; Bentzen SM; Daley FM; Dische S; Saunders MI; Richman PI; Wilson GD
Clin Cancer Res; 2004 Jun; 10(11):3745-54. PubMed ID: 15173081
[TBL] [Abstract][Full Text] [Related]
7. Squamous cell carcinoma of the oropharynx: Ki-67 and p53 can identify patients at high risk for local recurrence after surgery and postoperative radiotherapy.
Grabenbauer GG; Mühlfriedel C; Rödel F; Niedobitek G; Hornung J; Rödel C; Martus P; Iro H; Kirchner T; Steininger H; Sauer R; Weidenbecher M; Distel L
Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1041-50. PubMed ID: 11072161
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of Ki-67 (MIB1), PCNA and p53 in cancer of the oropharynx and oral cavity.
Sittel C; Ruiz S; Volling P; Kvasnicka HM; Jungehülsing M; Eckel HE
Oral Oncol; 1999 Nov; 35(6):583-9. PubMed ID: 10705094
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic relevance of proliferation marker Ki-67 (MIB 1), PCNA and p53 in combined surgically and radiologically treated cancers of the oropharynx and mouth cavity].
Sittel C; Ruiz S; Kvasnicka HM; Volling P; Jungehülsing M; Eckel HE
Laryngorhinootologie; 2000 Feb; 79(2):86-92. PubMed ID: 10738715
[TBL] [Abstract][Full Text] [Related]
10. ["Marker" of radioresistance in squamous cell carcinoma of the head and neck: a clinicopathologic and immunohistochemical study].
Budach W
Strahlenther Onkol; 1998 May; 174(5):286-8. PubMed ID: 9614960
[No Abstract] [Full Text] [Related]
11. p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma.
Shin DM; Lee JS; Lippman SM; Lee JJ; Tu ZN; Choi G; Heyne K; Shin HJ; Ro JY; Goepfert H; Hong WK; Hittelman WN
J Natl Cancer Inst; 1996 Apr; 88(8):519-29. PubMed ID: 8606380
[TBL] [Abstract][Full Text] [Related]
12. Predicting the effect of accelerated fractionation in postoperative radiotherapy for head and neck cancer based on molecular marker profiles: data from a randomized clinical trial.
Suwinski R; Jaworska M; Nikiel B; Grzegorz W; Bankowska-Wozniak M; Wojciech M; Krzysztof S; Dariusz L
Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):438-46. PubMed ID: 19733016
[TBL] [Abstract][Full Text] [Related]
13. p53 and Ki-67 as predictive markers for radiosensitivity in squamous cell carcinoma of the oral cavity? an immunohistochemical and clinicopathologic study.
Koelbl O; Rosenwald A; Haberl M; Müller J; Reuther J; Flentje M
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):147-54. PubMed ID: 11163508
[TBL] [Abstract][Full Text] [Related]
14. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
Zlotta AR; Noel JC; Fayt I; Drowart A; Van Vooren JP; Huygen K; Simon J; Schulman CC
J Urol; 1999 Mar; 161(3):792-8. PubMed ID: 10022686
[TBL] [Abstract][Full Text] [Related]
15. Molecular analysis of surgical margins in head and neck squamous cell carcinoma patients.
Nathan CO; Amirghahri N; Rice C; Abreo FW; Shi R; Stucker FJ
Laryngoscope; 2002 Dec; 112(12):2129-40. PubMed ID: 12461330
[TBL] [Abstract][Full Text] [Related]
16. Changes of mutant-type p53 expression in squamous cell carcinoma of the head and neck during radiation therapy and its clinical significance: comparison of an immunohistochemical method and PCR-SSCP assay.
Ogawa Y; Nishioka A; Hamada N; Terashima M; Inomata T; Yoshida S; Seguchi H; Kishimoto S
Oncol Rep; 1998; 5(5):1053-9. PubMed ID: 9683807
[TBL] [Abstract][Full Text] [Related]
17. Is p53 an independent prognostic factor in patients with laryngeal carcinoma?
Narayana A; Vaughan AT; Gunaratne S; Kathuria S; Walter SA; Reddy SP
Cancer; 1998 Jan; 82(2):286-91. PubMed ID: 9445184
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
[TBL] [Abstract][Full Text] [Related]
19. Expression of cyclins, p53, and Ki-67 in cervical squamous cell carcinomas: overexpression of cyclin A is a poor prognostic factor in stage Ib and II disease.
Shiohara S; Shiozawa T; Miyamoto T; Feng YZ; Kashima H; Kurai M; Suzuki A; Konishi I
Virchows Arch; 2005 Jun; 446(6):626-33. PubMed ID: 15891905
[TBL] [Abstract][Full Text] [Related]
20. Genomic amplification of Fanconi anemia complementation group A (FancA) in head and neck squamous cell carcinoma (HNSCC): Cellular mechanisms of radioresistance and clinical relevance.
Hess J; Unger K; Orth M; Schötz U; Schüttrumpf L; Zangen V; Gimenez-Aznar I; Michna A; Schneider L; Stamp R; Selmansberger M; Braselmann H; Hieber L; Drexler GA; Kuger S; Klein D; Jendrossek V; Friedl AA; Belka C; Zitzelsberger H; Lauber K
Cancer Lett; 2017 Feb; 386():87-99. PubMed ID: 27867017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
